83
Participants
Start Date
November 3, 2021
Primary Completion Date
September 30, 2024
Study Completion Date
March 31, 2025
efineptakin alfa
1200 μg/kg NT-I7 administered intramuscularly (IM) once every 6 weeks (Q6W) starting on Cycle 1. The treatment will be continued up to a maximum of 35 cycles (approximately 2 years).
Atezolizumab
1200 mg atezolizumab administered intravenously (IV) once every 3 weeks (Q3W) starting on Cycle 1. The treatment will be continued up to a maximum of 35 cycles (approximately 2 years).
TidalHealth Peninsula Regional, Inc., Salisbury
East Carolina University, Greenville
University Cancer and Blood Center, Athens
BRCR Medical Center, Plantation
Florida Cancer Specialists - East Research Office, West Palm Beach
Florida Cancer Specialists - North Research Office, St. Petersburg
Florida Cancer Specialists - South Research Office, Fort Myers
University of South Alabama, Mobile
Tennessee Oncology - Nashville, Nashville
Tennessee Oncology - Chattanooga, Chattanooga
Thompson Cancer Survival Center, Knoxville
Norton Cancer Institute, Louisville
Pikeville Medical Center, Inc., Pikeville
Zangmeister Cancer Center, Columbus
Goshen Center for Cancer Care, Goshen
Renovatio Clinical - The Woodlands, The Woodlands
Renovatio Clinical - El Paso, El Paso
TOI Clinical Research, Cerritos
OHSU Knight Cancer Institute, Portland
Eastern CT Hematology & Oncology Associates, Norwich
MaineHealth Cancer Care, South Portland
Summit Health Medical Center, Florham Park
Lead Sponsor
Roche Pharma AG
INDUSTRY
NeoImmuneTech
INDUSTRY